The investigators suggested that NGAL and MMP-9/NGAL complex levels should be further evaluated in patients with PCOS, because the decreased levels of these atherogenic molecules might protect patients with PCOS against cardiovascular disease (CVD). This evidence concerns the gene MMP9 and cardiovascular disorder.